pyrroles has been researched along with Muscle Weakness in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Atas, N; Babaoglu, H; Salman, R; Satis, H; Tufan, A; Varan, O | 1 |
| Chen, B; Guan, YX; Huang, W; Jing, F; Ma, Q; Wu, CJ; Xu, SJ | 1 |
| Laaksonen, R | 1 |
| Amato, AA; Puig, A; Scripko, PD | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Krossnes, BK; Ljøstad, U; Mygland, Å | 1 |
| Clarkson, PM; Grimaldi, AS; Haller, RG; Hoffman, EP; Levine, BD; Parker, BA; Pescatello, LS; Thompson, PD; White, CM | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Desplaces, N; Gabignon, C; Le Guyader, N; Lidove, O; Zeller, V; Ziza, JM | 1 |
| Mongini, T; Musumeci, O; Olivero, N; Palmucci, L; Rodolico, C; Vercelli, L | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
1 trial(s) available for pyrroles and Muscle Weakness
| Article | Year |
|---|---|
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Creatine Kinase; Decision Trees; Double-Blind Method; Exercise Test; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isometric Contraction; Male; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Muscle Weakness; Muscle, Skeletal; Physical Endurance; Pyrroles; Research Design; Surveys and Questionnaires | 2010 |
11 other study(ies) available for pyrroles and Muscle Weakness
| Article | Year |
|---|---|
Tofacitinib for the Treatment of Refractory Polymyositis.
Topics: Antirheumatic Agents; Biopsy; Disease Progression; Drug Resistance, Multiple; Electromyography; Female; Humans; Janus Kinase Inhibitors; Medication Therapy Management; Middle Aged; Monitoring, Immunologic; Muscle Strength; Muscle Weakness; Piperidines; Polymyositis; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model.
Topics: Animals; Female; Lymphocyte Activation; Muscle Weakness; Myasthenia Gravis, Autoimmune, Experimental; Pyrroles; Quinazolines; Rats; Rats, Inbred Lew; T-Lymphocytes, Helper-Inducer | 2020 |
STOMPing forward: statins, muscle complaints and CK.
Topics: Atherosclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscle, Skeletal; Muscles; Muscular Diseases; Myalgia; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
Mystery case: a 63-year-old man with progressive proximal pain and weakness.
Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed | 2014 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
Persisting weakness after withdrawal of a statin.
Topics: Aged, 80 and over; Atorvastatin; Autoimmune Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Myositis; Necrosis; Pyrroles | 2014 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
[Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid].
Topics: Aged; Anti-Bacterial Agents; Atorvastatin; Creatine Kinase; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle Weakness; Prosthesis-Related Infections; Pyrroles; Rhabdomyolysis; Staphylococcal Infections | 2013 |
Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment.
Topics: Aged; Ascomycota; Atorvastatin; Biological Products; Coenzymes; Creatine Kinase; Dietary Supplements; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle Weakness; Muscle, Skeletal; Pyrroles; Ubiquinone | 2006 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |